|
|
|
|
|
|
|
P.I.:
|
Melanie Palomares, MD, MS
|
(Cooperative Group)
|
|
Title:
|
SWOG S0812: Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
|
| | |
|
|
|
|
|
|
P.I.:
|
Jae Kim, MD
|
(Institutional)
|
|
Title:
|
Tissue and Blood and Prospective Database Establishment for Molecular, Biochemical, and Histological Study of Thoracic Diseases
|
|
|
|
|
|
|
P.I.:
|
David Snyder, MD
|
(Industrial)
|
|
Title:
|
Comparative Evaluation of the Cepheid Xpert BCR-ABL Monitor Assays
|
|
|
|
|
|
|
P.I.:
|
Anthony Stein, MD
|
(Industrial)
|
|
Title:
|
An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
|
| | |
|
|
|
|
|
|
P.I.:
|
Sumanta Pal, MD
|
(Industrial)
|
|
Title:
|
A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects with Advanced Malignancies Previously Enrolled in Other XL184 Studies
|
|
|
|
|
|
|
P.I.:
|
Przemyslaw Twardowski, MD
|
(Industrial)
|
|
Title:
|
A Randomized, Double-Blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma
|
| | |
|
|
|
|
|
|
P.I.:
|
Jana Portnow, MD
|
(Industrial)
|
|
Title:
|
A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme
|
| | |
|
|
|
|
|
|
P.I.:
|
George Somlo, MD
|
(Institutional)
|
|
Title:
|
Phase II Trial of Neoadjuvant Chemotherapy with Carboplatin and NAB-Paclitaxel in Patients with Locally Advanced and Inflammatory Triple Negative Breast Cancer
|
| | |
|
|
|
|
|
|
P.I.:
|
Jana Portnow, MD
|
(Cooperative Group)
|
|
Title:
|
RTOG 0929: A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
|
| | |
|
|
|
|
|
|
P.I.:
|
Richard Pezner, MD
|
(Cooperative Group)
|
|
Title:
|
ACOSOG Z4099/RTOG 1021: A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
|
| | |
|
|
|
|
|
|
P.I.:
|
Anna Pawlowska, MD
|
(Cooperative Group)
|
|
Title:
|
COG ACCL0934: A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
|
| | |
|
|
|
|
|
|
P.I.:
|
Kimlin Ashing-Giwa, PhD
|
(NCI Approved External Peer Review)
|
|
Title:
|
Administrative Supplement to Expand NCI-Supported Community Outreach Capacity through Community Health Educators (CHEs) of the National Outreach Network
|
| | |
|
|
|
|
|
|
P.I.:
|
Robert Chen, MD
|
(Institutional)
|
|
Title:
|
Acquisition of Peripheral Blood and/or Bone Marrow Aspirate from Patients with Chronic Lymphocytic Leukemia for Method Development of
Aptamers Based Delivery Method of RNAi
|
|
|
|
|
|
|
P.I.:
|
Vincent Chung, MD
|
(Industrial)
|
|
Title:
|
A Phase I, Open-Label Multi-Center, Randomized Crossover Study to Assess the Bioequivalence of 2 Formulations TKI258, FMI Capsule and FMI Tablet, in Patients with Advanced Solid Tumors
|
| | |
|
|
|
|
|
|
P.I.:
|
Sumanta Pal, MD
|
(Institutional)
|
|
Title:
|
Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
|
| | |
|
|
|
|
|
|
P.I.:
|
Robert Morgan, MD
|
(Industrial)
|
|
Title:
|
An Open Label, Multi-Center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States who are Currently Benefiting or who have Benefited from Gefitinib Treatment
|
|
|
|
|
|
|
P.I.:
|
George Somlo, MD
|
(Institutional)
|
|
Title:
|
Q3Week Carboplatin with Weekly Abraxane and Trastuzumab as Neoadjuvant Therapy in Resectable and Unresectable (Stage IIA-IIIC)HER2-Positive Breast Cancer: A BrUOG Phase II Study BrUOG-BR-211B
|
| | |
|
|
|
|
|
|
P.I.:
|
Nayana Vora, MD
|
(Cooperative Group)
|
|
Title:
|
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
|
| | |
|
|
|
|
|
|
P.I.:
|
Anthony Stein, MD
|
(Institutional)
|
|
Title:
|
Phase 2 Study of Clofarabine with High Dose Cytarabine and G-CSF Priminig in Adult Patients Less Than Age 65 with Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
|
| | |
|
|
|
|
|
|
P.I.:
|
Arti Hurria, MD
|
(NCI Approved External Peer Review)
|
|
Title:
|
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
|
| | |
|
|
|
|
|
|
P.I.:
|
Ji-lian Cai, MD
|
(Industrial)
|
|
Title:
|
An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects with Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) after Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
|
| | |
|
|
|
|
|
|
P.I.:
|
Lily Lai, MD
|
(Industrial)
|
|
Title:
|
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
|
|
|
|
|
|
|
P.I.:
|
Kimlin Ashing-Giwa, PhD
|
(NCI Approved External Peer Review)
|
|
Title:
|
Sister Survivor: Improving the Survivorship Care of African-American Women with Breast Cancer
|
| | |
|
|
|
|
|
|
P.I.:
|
Michael Rosenzweig, MD
|
(Industrial)
|
|
Title:
|
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
|
| | |
|
|
|
|
|
|
P.I.:
|
Jay Thomas, MD, PhD
|
(Institutional)
|
|
Title:
|
Archstone Spiritual Care Demonstration Project: Outcomes for Patients, Families, and Staff
|
| | |
|